Holen Sie sich die Stockscreener-App
26.89
6.86%
-1.98
Handel nachbörslich:
26.92
0.03
+0.11%
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com
(CRNX) Trading Report - news.stocktradersdaily.com
Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia
Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
US Bancorp DE Sells 5,176 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Where are the Opportunities in (CRNX) - Stock Traders Daily
Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews
Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq
Crinetics Awards Major Stock Grants to 17 New Hires Including Executive - Stock Titan
Proficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals - TipRanks
Principal Financial Group Inc. Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharma’s Earnings Call: Progress Amid Challenges - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 6.1% on Better-Than-Expected Earnings - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance UK
Cantor Fitzgerald lifts Crinetics stock target to $100 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year LowHere's What Happened - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Announces Earnings Results - MarketBeat
Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating - TipRanks
Crinetics price target lowered to $91 from $92 at Citizens JMP - TipRanks
Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development - TipRanks
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus.com
Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials - TipRanks
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Crinetics Pharmaceuticals: Financial Results and Future Plans - TipRanks
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):